3 ms·
That's my first guess too, but these long terms effects seem fairly rare (esp. cytokine storm-related) and I'm not convinced the trial population would be big e
by totony 6y ago
That's my first guess too, but these long terms effects seem fairly rare (esp. cytokine storm-related) and I'm not convinced the trial population would be big enough to take this into account.
- ksaj 6y agoModerna's third stage trial consisted of 30,000 recipients (presumably that means 15,000 since half of them would have received a placebo.) Added with the previous two trials, you'd expect even the rarest reactions to start showing up already. You can expect that if there are indeed super-rare novel responses, they'll come to light over the approximately year-long roll out. Additionally, even though vaccines will be rolling out, Moderna is holding 88 trials over the next 2 years. So they're not just ending the trials and injecting everyone they can. That's just the one company. Pfizer and the others should be similar.